Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
about
Molecular pathology of prostate cancerThe RNA-binding protein Sam68 modulates the alternative splicing of Bcl-xReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsSAM68: Signal Transduction and RNA Metabolism in Human CancerAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesThe RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cellsAlternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn.The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumorsA novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells.The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.Splicing programs and cancerNovel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures.Nonreceptor tyrosine kinases in prostate cancer.C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasisTargeting the RNA-binding protein Sam68 as a treatment for cancer?Role of Sam68 in post-transcriptional gene regulation.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Targeting tyrosine kinases and autophagy in prostate cancer.Steps in prostate cancer progression that lead to bone metastasisAlternative splicing programs in prostate cancer.Molecular pathways in prostate cancer.The SCF/c-KIT system in the male: Survival strategies in fertility and cancer.Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity.Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.The p53 status can influence the role of Sam68 in tumorigenesis.Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.An emerging role for nuclear RNA-mediated responses to genotoxic stress.KIT variants in bovine ovarian cells and corpus luteum.Interaction and functional cooperation between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor.The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers.RET rearrangements are actionable alterations in breast cancer
P2860
Q24672410-ABF6432F-E3E7-46A1-BAB9-83E1AA32DD96Q24683323-A1E23C63-AF8E-46F9-93F4-00585CEB3B2CQ26740953-CE162FBE-11A1-44B3-B039-EB8B2C3ADC7DQ26798149-C2AA236C-AA37-4D48-96A7-9B265150FB73Q26866135-305A12BF-2A26-4EDB-AAB8-A950D77E9AAEQ28284196-56D001CB-BC72-4D1E-85C0-BA64C3918C0BQ30157097-93A0A5FA-C12B-4988-83E4-9E07F02FF598Q30370955-EA586324-DC40-4154-9A5B-C296DC2DF01CQ33324395-0C7D63DB-E370-485A-9A9B-1993F034BD5EQ33590893-25AE8BD2-9864-4441-A89C-F874F4138DB9Q35052156-6A9824A3-5281-44CC-B420-6C001933C1C5Q35450183-8B15FE90-9177-416E-A392-617EF6C0B5CFQ36580194-6F0B5717-3404-4BA1-B7EC-6179A509BAC7Q36759212-699AD0EA-8620-4165-88FD-B2DC069DA3E3Q36840289-DE7BCA3B-BFAD-42D4-A450-8058A9E13133Q36967302-DE5F88B0-22FC-412A-A36D-8347902071F9Q37420837-FC7C9794-A1CF-47E3-B6F7-56570EC0B5D7Q37705831-122AD868-6844-4815-A709-0E92EF9110B4Q37847052-A3CEED72-D2F4-44A4-9477-4A2BA50F8718Q37848782-2D656BB4-3679-4606-9FD6-99EE951D6C70Q38132132-0F1C9373-E93B-4C03-98B2-4D8AE9FA6812Q38166735-795780E5-9BA4-4799-86EB-146393A548F1Q38264052-DB6476E8-C238-44AD-84A5-463D40C7DC13Q38673511-989FB0B1-EE17-45C7-89F1-6306CDFA3F7FQ38897955-05139D3E-9944-461C-B768-5A3795F93ADDQ39401758-BA460C72-D656-4267-B3E3-0F920F89EC83Q39505285-DA4D862B-20D4-4CC0-BCB7-D02CA116D6C9Q39899689-771B9000-6790-4491-88CB-F75B5F908B90Q40091176-B71D104E-62D6-48E0-A1B4-85E5FFFD1F26Q41883889-5178E97E-1BDB-423E-9EC0-59651BEE6B33Q42008721-BCE1C2C9-E780-4564-A090-228D6E777472Q42710426-826ED711-5BBB-48C9-ADBF-D35585BB5A3CQ46117855-55145499-D445-4410-B3FF-E081889482E2Q46697547-9AD48DA9-32FE-45F7-A8F9-34D345B0B5AAQ46971533-C1B84D25-DEA2-494B-854E-357E68A1B2FCQ59136613-52779BB0-9C6A-4A9A-A598-225BF3E89383
P2860
Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Expression of a truncated form ...... ase in human prostatic cancer.
@en
type
label
Expression of a truncated form ...... ase in human prostatic cancer.
@en
prefLabel
Expression of a truncated form ...... ase in human prostatic cancer.
@en
P2093
P2860
P1476
Expression of a truncated form ...... ase in human prostatic cancer.
@en
P2093
Claudio Sette
Donatella Farini
Giovanni Maturo
Giuseppe Vespasiani
Innocenzo Sammarco
Maria Paola Paronetto
Pellegrino Rossi
Raffaele Geremia
P2860
P304
P356
10.1016/S0002-9440(10)63212-9
P407
P577
2004-04-01T00:00:00Z